Turn Therapeutics Inc. (TTRX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Turn Therapeutics reported revenue of $0. Net income was -$3.2M, or -$0.12 per diluted share. Operating activities generated -$2.6M of cash, leaving -$2.6M of free cash flow. At fiscal year end, Turn Therapeutics held $12.2M in total assets against $7.5M in total liabilities, including $4.0M of cash and equivalents.
Open the full interactive Turn Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Turn Therapeutics Key Stats
| Share Price | $10.60 |
|---|---|
| Market Cap | $315.8M |
| 52-Week Range | $2.71 – $15.34 |
| Shares Outstanding | 29.8 million (basic, 2026 Q2) |
Turn Therapeutics Income Statement
| FY 2025 | |
|---|---|
| Revenue | $0 |
| Operating Income | -$5.9M |
| Pre-Tax Income | -$3.2M |
| Net Income | -$3.2M |
| Diluted EPS | -$0.12 |
Turn Therapeutics Quarterly Results
| 2025 Q3 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Income | -$1.9M | -$970,972 | -$5.8M |
| Diluted EPS | -$0.07 | -$0.03 | -$0.20 |
Turn Therapeutics Balance Sheet
| FY 2025 | |
|---|---|
| Cash & Equivalents | $4.0M |
| Current Assets | $5.2M |
| Total Assets | $12.2M |
| Current Liabilities | $6.0M |
| Total Liabilities | $7.5M |
| Shareholders' Equity | $4.7M |
Turn Therapeutics Cash Flow Statement
| FY 2025 | |
|---|---|
| Cash From Operations | -$2.6M |
| Cash From Investing | -$152,986 |
| Cash From Financing | $6.9M |
| Free Cash Flow | -$2.6M |
Figures from Turn Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Turn Therapeutics financials page for every line item.
Turn Therapeutics Company Profile
| Ticker | TTRX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Westlake Village, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0002023016 |
Frequently Asked Questions
What was Turn Therapeutics' revenue in fiscal 2025?
Turn Therapeutics (TTRX) reported revenue of $0 for fiscal 2025.
What was Turn Therapeutics' net income in fiscal 2025?
Turn Therapeutics reported net income of -$3.2M for fiscal 2025.
What was Turn Therapeutics' earnings per share (EPS) in fiscal 2025?
Turn Therapeutics' diluted EPS was -$0.12 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Turn Therapeutics generate in fiscal 2025?
Turn Therapeutics generated -$2.6M of free cash flow in fiscal 2025.
What was Turn Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Turn Therapeutics reported revenue of $0.
How many shares of Turn Therapeutics are outstanding?
Turn Therapeutics reported a weighted average of 29.8 million basic shares outstanding in 2026 Q2.
What is Turn Therapeutics' market cap?
Based on its latest closing price, Turn Therapeutics (TTRX) has a market capitalization of about $315.8M.
When does Turn Therapeutics' fiscal year end?
Turn Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Turn Therapeutics headquartered?
Turn Therapeutics lists its business address in Westlake Village, California in its SEC filings.